Lilly’s weight loss drug reduces diabetes risk in overweight patients
Eli Lilly’s weight-loss drug Zepbound dramatically reduces the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the drug’s maker said Tuesday.
POPULAR POSTS
Putin may discuss Ukraine peace deal with Trump
November 22, 2024
Spain’s vice-president Ribera blames floods on climate change
November 22, 2024
Storm lashes northwestern US, killing two people
November 22, 2024
Iceland volcano erupts for tenth time in three years
November 22, 2024
LIVE STREAM